Shared by 
Unlock all 10 pages
Get it free by sharing your own notes, buy just this one, or become a member and unlock documents with your plan.
How to unlock this document
Choose the way that suits you. Each one gives you all 10 pages to read online and the PDF to download.
Share your notes, unlock for free
2 free unlocks for every 5 approved uploads
- Upload your own lecture notes, assignments, essays or past papers
- PDF, Word, PowerPoint and Excel files all work, and you can send many at once
- We check each upload; you get a notification when it is approved
- Spend a free unlock on this document or any other, and keep it for good
- Shared under your public username, never your email
Then upload your notes from your profile.
Buy this document
$10 one-time payment
- All 10 pages of this document, yours to keep
- Download the PDF and read it any time, also offline
- No subscription and nothing to cancel
- Find it again any time under My Profile → Library
You log in or create a free account first, then pay securely.
Become a member
Unlock documents from the whole library, which keeps growing
- Choose any documents you like, up to your plan’s unlocks
- Documents you unlock stay yours, even if you cancel later
- Your unlocks start again with every renewal
- Secure checkout by Dodo Payments
You log in or create a free account first, then pay securely.
Compare the plansAlready a member, or bought this before? Log in to open it
About this document
- Pages
- 10 pages
- Price
- $10 one-time, yours to keep
- Membership
- Included in every plan
- Format
- Subject
- Accounting, Business, Management
This document is a case study of PT Indofarma, a pharmaceutical company in Indonesia. It covers the company’s history, the financial issues it faced, and the regulatory actions taken against it. It is useful for students studying business cases, accounting, or management.
What's inside
- History of PT Indofarma
- Financial issues and regulatory actions
- Factors causing the company's losses
- Comparison with other companies
- Management's response to the crisis
Who it is for: Students of Business, Accounting, or Management studying business cases. (Undergraduate)
Share with classmates: WhatsApp Telegram X LinkedIn Facebook
Summary
PT Indofarma is a pharmaceutical company. It discusses the company's history, financial issues and regulatory actions taken against it.
Company History
PT Indofarma started as a government-owned pharmacy. It became a public company in 1996. The document covers the company's name changes and ownership history.
Financial Issues
PT Indofarma hid losses for two years. The company overstated its inventory and understated its cost of goods sold. This affected its net profit.
Regulatory Actions
The Capital Market Supervisory Agency (BAPEPAM) investigated PT Indofarma. It found violations of financial reporting standards. The agency imposed administrative sanctions.
Factors of Loss
PT Indofarma faced internal and external factors causing losses. These include intense competition, generic drug dependence, and inefficient production.
Key terms
- PT Indofarma
- A pharmaceutical company that became a public company in 1996.
- BAPEPAM
- The Capital Market Supervisory Agency in Indonesia.
- Overstated inventory
- Inventory valued higher than it should be.
- Understated cost of goods sold
- Cost of goods sold valued lower than it should be.
- Administrative sanctions
- Penalties imposed by BAPEPAM for financial reporting violations.
- PSAK
- Financial accounting standards in Indonesia.
Questions this document helps with
- Why did PT Indofarma hide its losses?
- What actions did BAPEPAM take against PT Indofarma?
- How did PT Indofarma's financial reporting violate PSAK?
Summary written with AI from the document's text.
Ask the AI Teacher
Ask any question about this document or your course, and get a clear explanation.
Log in to ask Create a free account
Free accounts can ask 5 questions a day.